CAG
BIS icon

Csenge Advisory Group’s ProShares UltraShort NASDAQ Biotechnology BIS Stock Holding History

Csenge Advisory Group’s Portfolio BIS Stock Details BIS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-6,211
Closed -$163K – 716
2025
Q3 		$163K Buy
+6,211
New +$185K 0.01% 668

Other funds holding BIS

Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Csenge Advisory Group's BIS Position: Q4 2025 in Review

Csenge Advisory Group sold out of ProShares UltraShort NASDAQ Biotechnology (BIS) in Q4 2025, closing a stake of 6,211 shares — an estimated $163K sold.

Csenge Advisory Group first reported a position in BIS in Q3 2025 and held it in 1 quarter. The position peaked at $163K in Q3 2025. 4 funds tracked by Wall St. Rank hold BIS as of Q4 2025.

  • Csenge Advisory Group reported no remaining ProShares UltraShort NASDAQ Biotechnology position as of Q4 2025 after selling out during the quarter.
  • Csenge Advisory Group sold 6,211 ProShares UltraShort NASDAQ Biotechnology shares in Q4 2025, an estimated $163K.
  • Csenge Advisory Group first reported a position in ProShares UltraShort NASDAQ Biotechnology in Q3 2025 and held it in 1 quarter.
  • Csenge Advisory Group's ProShares UltraShort NASDAQ Biotechnology position peaked at $163K in Q3 2025.
  • 4 funds tracked by Wall St. Rank held ProShares UltraShort NASDAQ Biotechnology as of Q4 2025.

Based on Csenge Advisory Group's 13F filing for Q4 2025, filed 6 Feb 2026.